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Box 90Abstract—Overly aggressive prostate cancer (PCa) treatment adversely affects patients and places an unnecessary
burden on our health care system. The inability to identify and grade clinically significant PCa lesions is a factor
contributing to excessively aggressive PCa treatment, such as radical prostatectomy, instead of more focal,
prostate-sparing procedures such as cryotherapy and high-dose radiation therapy. We have performed 3-D in vivo
B-mode and acoustic radiation force impulse (ARFI) imaging using a mechanically rotated, side-fire endorectal im-
aging array to identify regions suspicious forPCa in29patientsbeing treatedwith radical prostatectomies forbiopsy-
confirmed PCa. Whole-mount histopathology analyses were performed to identify regions of clinically significant/
insignificant PCa lesions, atrophy and benign prostatic hyperplasia. Regions of suspicion for PCa were reader-
identified in ARFI images based on boundary delineation, contrast, texture and location. These regions of suspicion
were comparedwith histopathology identified lesions using a nearest-neighbor regional localization approach.Of all
clinically significant lesions identified on histopathology, 71.4% were also identified using ARFI imaging, including
79.3% of posterior and 33.3% of anterior lesions. Among the ARFI-identified lesions, 79.3% corresponded to clin-
ically significant PCa lesions, with these lesions having higher indices of suspicion than clinically insignificant PCa.
ARFI imaging had greater sensitivity for posterior versus anterior lesions because of greater displacement signal-
to-noise ratio and finer spatial sampling. Atrophy and benign prostatic hyperplasia can cause appreciable prostate
anatomy distortion and heterogeneity that confounds ARFI PCa lesion identification; however, in general, ARFI
regions of suspicion did not coincide with these benign pathologies. (E-mail: mark.palmeri@duke.edu)  2016
The Authors. Published by Elsevier Inc. on behalf of World Federation for Ultrasound in Medicine & Biology.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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B-Mode ultrasound is the primary imaging tool used dur-
ing prostate biopsy procedures, but it offers limited sensi-
tivity and specificity for prostate cancer (PCa) lesion
detection (Correas et al. 2013; Salomon et al. 2008),
forcing urologists to rely on systematic biopsy sampling
methods for diagnosing cancer and making treatment
decisions. The multifocal nature of PCa means
systematic sampling often samples only a subset of the
clinically significant disease in the gland, makingddress correspondence to: Mark L. Palmeri, 136 Hudson Hall,
281, Durham,NC 27708, USA. E-mail: mark.palmeri@duke.edu
1251treatment decisions challenging for urologists (Cornud
et al. 2012; Mufarrij et al. 2010). Image-guided, targeted
biopsy has the potential to improve diagnostic confi-
dence, allowing for more informed treatment decisions,
facilitating more conservative focal therapies and
ultimately resulting in better patient outcomes.
Magnetic resonance imaging (MRI) has been used to
diagnose PCa since the early 1980s, but early studies on
its diagnostic accuracy indicated significant variability
(Gupta et al. 2013). The recent augmentation of MR se-
quences with functional parameters has yielded prom-
ising results (Gupta et al. 2013; Hricak et al. 2007;
Raskolnikov et al. 2014; Rastinehad et al. 2014).
Among the MRI sequences currently used in the study
Fig. 1. B-Mode/acoustic radiation force impulse imaging setup
with the ER7B ultrasound transducer integrated into a custom-
rotating CIVCO transducer holder to obtain 3-D ultrasound data
sets with the Siemens Acuson SC2000 scanner.
1252 Ultrasound in Medicine and Biology Volume 42, Number 6, 2016of PCa, it is well established that T2-weighted imaging
(T2WI) offers the best assessment of prostate anatomy
based on its ability to delineate prostate capsule margins,
distinguish internal structures and differentiate among the
glandular zones (peripheral zone and central gland), and
the addition of apparent diffusion coefficient (ADC)
maps aids in PCa identification (Gupta et al. 2013).
Although MRI is showing promise in diagnosing PCa
and guiding treatment decisions, it is not a real-time imaging
modality and is associated with considerable resource over-
head, including time and expense, which has motivated the
development of novel ultrasound imaging technologies to
approach this problem. Hoyt et al. (2008) and Taylor et al.
(2005) explored elasticity as a mechanism of delineating
PCa using a sonoelastography crawling wave approach.
Mahdavi et al. (2011) developed an ultrasonic vibro-
elastography method that characterizes the viscoelastic
properties of the prostate to delineate prostate anatomy,
guide PCa diagnosis and delineate regions of PCa suspicion.
Vibro-elastography is also being studied in combination
with prostate MRI to improve prostate cancer detection
(Ashab et al. 2015). Shear wave elastography (SWE)
(Barr et al. 2012) and strain-based elastography
(Knig et al. 2005; Pallwein et al. 2008) have also been
found to have diagnostic value in identifying PCa lesions
based on their mechanical properties.
Preliminary studies have indicated that acoustic ra-
diation force impulse (ARFI) imaging, an ultrasonic,
elasticity-based imaging modality, can delineate PCa
and prostate anatomy with high fidelity (Palmeri et al.
2015; Zhai et al. 2010; 2012). ARFI imaging has short
acquisition times, low cost and portability that could be
used to guide targeted biopsies in outpatient clinical
settings. Toward the goal of quantifying the diagnostic
capabilities of ARFI imaging, we recruited 29 patients
with biopsy-confirmed PCa who were undergoing radical
prostatectomy, identified regions in in vivo ARFI images
that were suspicious for cancer (regions of suspicion
[ROS]) and compared these ARFI image findings with
those for whole-mount histopathology. Given the chal-
lenges associated with reconstructing imaged prostate
volumes from whole-mount histology slides, we used a
nearest-neighbor regional match approach to localize
lesions and ROS to evaluate the ability of ARFI to iden-
tify clinically significant PCa lesions. Finally, regions of
atrophy and benign prostatic hyperplasia (BPH) were
identified on histopathology and evaluated as potential
confounders when identifying ROS in ARFI images.
METHODS
ARFI and B-mode image acquisition and image
analysis
Experimental B-mode and ARFI prostate images
were acquired in 29 patients with biopsy-confirmedPCa immediately before radical prostatectomy in an insti-
tutional review board-approved study after obtaining
written informed consent. Imaging was performed using
a modified Siemens Acuson SC2000 scanner (Siemens
Medical Solutions, Ultrasound Division, Mountain
View, CA, USA) with an Acuson ER7B side-fire
transrectal probe coupled to a mechanical rotation
device (Fig. 1).
Images were acquired in the sagittal plane using a
three-focal-zone acoustic radiation force excitation fired
in rapid succession to create a virtual, extended acoustic
radiation force excitation (Rosenzweig et al. 2015;
Bercoff et al. 2004) to interrogate the entire prostate
with adequate displacement amplitudes and a relatively
uniform excitation beam width. Table 1 details the fre-
quencies, focal configurations and excitation durations
used at each focal depth. Eighty-two excitations, spaced
0.67 mm apart, were used for each imaging plane,
achieving a 55-mm field of view for each imaging plane.
Raw baseband (in-phase and quadrature [IQ]) data
were acquired at an 8-kHz pulse repetition frequency
for 5 ms using tracking beams focused at 60 mm at
5.0 MHz in an F/3 focal configuration with dynamic
receive. Track beams were acquired using 4:1
parallel receive with 0.17-mm track beam spacing
(Dahl et al. 2007), and data were saved for offline
displacement estimation.
The ARFI tracking beams were optimized for
displacement estimation over the extended focal zone
ARF excitation, and the reconstructed B-mode images
from these data did not achieve the highest spatial resolu-
tion possible with the ER7B transducer. High-resolution
B-mode images were acquired in a subsequent data
acquisition using 126 transmits spanning a 55-mm field
of view with 7:1 parallel receive, coherent beamforming.
These B-mode sequences used a 7.0-MHz transmit fre-
quency with an F/3 focal configuration at a fixed focal
depth dependent on the size of the prostate, which ranged
Table 1. Acoustic radiation force focal configurations
used to interrogate each imaging plane of the prostate*
Focal depth (mm) F/# Frequency (MHz) No. of cycles
15.0 2.35 5.4 300
22.5 2.0 4.6 300
30.0 2.0 4.6 300
* The frequencies and focal configurations were chosen to maintain a
uniform beam width of 0.67 mm throughout the extended region of
excitation. Excitation beams were spaced 0.67 mm, with 82 excitations
per imaging plane for a 55-mm imaging plane field of view.
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dynamic receive focal configuration was used for receive
beamforming.
Three-dimensional prostate volumes were populated
by mechanically rotating the ER7B probe in 1 eleva-
tion increments between image acquisitions, sweeping
an arc across the lateral extent of the prostate (Fig. 2).
This rotation setup used a CIVCOMicro-Touch stabilizer
(CIVCOMedical Solutions, Kalona, IAUSA) with 6-axis
degrees of freedom for manual positioning of the trans-
ducer to sweep through the entire prostate during
imaging. A custom optical angular feedback transductionFig. 2. Orientation of the swept imaging volume (blue outline)
relative to the prostate and adjacent anatomy. B-Mode and
acoustic radiation force impulse images were acquired in sepa-
rate sweeps of this volume in 1 increments.circuit using a reflective linear strip with 212-line-per-
inch resolution (US Digital, Vancouver, WA, USA) was
coupled to the transducer-holding cradle (Fig. 1) and
communicated with a QSB-S Quadrature-to-USB adapter
to achieve 9-line/degree resolution. Rotation was
performed with a 141-oz-in torque stepper motor with a
planetary gearbox (Model 11 YPG202 S-LW4-R27,
Anaheim Automation, Anaheim, CA, USA) to achieve
accurate spatial localization of the imaging frames in
the 3-D data set.
Acoustic radiation force impulse image displace-
ments were estimated using Loupas’ algorithm
(Loupas et al. 1995), applying a correlation coefficient
threshold of 0.95 to discard estimates corrupted by
motion and noise. Displacement data from each focal
depth were normalized to account for depth-dependent
variations in ARFI amplitude (Palmeri et al. 2015). The
imaging planes of displacement data were scan converted
to an isotropic voxel size of 0.153 0.153 0.15 mm3 for
image analysis in 3-D Slicer (Fedorov et al. 2012; Palmeri
et al. 2015). Prostate anatomic features, including the
prostate capsule and central gland, were identified,
segmented, modeled and used for anatomic guidance
during ROS identification (Palmeri et al. 2015). ROS
were identified blinded to histopathology and assigned
an index of suspicion (IOS) score based on a 3-point scale
(Table 2). Axial, coronal and sagittal imaging planes were
all used to assign IOS scores. ROS were segmented and
modeled in 3-D Slicer.
Histopathology analysis
All ARFI-imaged prostates were radically excised
and whole mounted for histologic evaluation with hema-
toxylin and eosin (H&E) stain. Two trained pathologists
identified the outer capsule, verumontanum and Gleason
grade of PCa lesions, along with benign processes,
including BPH and atrophy.
Histopathology slides were digitized using an Epson
750 Pro scanner (Epson America, Long Beach, CA,
USA) at 600-dpi resolution and converted toTable 2. Description of IOS scores for ARFI imaging
ROS*
IOS score
ARFI imaging ROS characteristics
Boundary Contrast Texture Location
1 Variable Low Variable Peripheral zone or
central gland
2 Variable Medium Smooth Peripheral zone
3 Well defined High Smooth Peripheral zone
ARFI5 acoustic radiation force impulse; IOS 5 index of suspicion;
ROS 5 regions of suspicion.
* Note that the healthy central gland exhibits heterogeneity in ARFI
images that can confound the ability to identify ROS and, therefore, re-
duces this IOS in this scoring scheme.
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image stacks using ImageJ (Schneider et al. 2012). Vol-
ume estimates were computed for all histology- identified
PCa lesions in five steps:
1. Approximate overall prostate volume as an ellipsoid
using pathology triaxial measurements from just after
prostate excision (Palmeri et al. 2015).
2. Segment PCa lesion and prostate capsule outline on all
slides in 3-D Slicer.
3. Sum the total area of PCa lesion segmentations across
all histology slides.
4. Divide the total area of PCa lesion by the total area of
prostate capsule summed across slides to compute a
total lesion area fraction.
5. Multiply total lesion area fraction by approximated
ellipsoid prostate volume to obtain approximated
PCa lesion volume.Fig. 3. Procedure for localizing acoustic radiation force
impulse image ROS. Step 1: Localize the ROS (green subvo-
lume in model) to the prostate base, mid- or apex region.
Step 2: Localize the ROS (green outline, IOS 5 3) to the pros-
tate anterior or posterior region. The magenta outline represents
the prostate capsule, and the blue outline represents the central
gland outline. Step 3: Localize the ROS to the right or left. Step
4: Determine the single region that corresponds best to the
bulk of the ROS burden. Photographs of segmented prostate
reproduced, with permission, from Dickinson et al.
(2011). ROS 5 regions of suspicion.ARFI imaging and histopathology correlation
The slice thickness and orientation of whole-mount
histology slides were approximated during the slide
registration process, making voxel-to-voxel comparisons
between histology and imaging volumes challenging.
For this reason, we chose to correlate ARFI image
ROS to delineated histology lesions using a 27-region
model of the prostate, where each region is defined by
anatomic location in the prostate (Dickinson et al.
2011). This regional localization procedure involved
three steps:
1. Visual localization of ARFI image and histopathology
models to a 27-region, standardized grid (Fig. 3)
(Dickinson et al. 2011).
2. Approximation of the ARFI image ROS and histopa-
thology lesion centers.
3. Evaluation of the matches between the centers of
ARFI image ROS and histopathology lesions on the
27-region grid.
Acoustic radiation force impulse image models
(prostate capsule, central gland, ROS) and histopathology
slides were visually registered to a standardized
27-region grid using anatomic features as fiducials
(Dickinson et al. 2011). The centers of the ARFI image
ROS and histopathology lesions were then found by iter-
atively reducing the space of possible center locations on
the 27-region grid to one center region in four steps
(Fig. 3):
1. Localize the ROS to the prostate base, mid- or apex
region, reducing the number of possible regions
from 27 to 9.
2. Localize the ROS to the anterior or posterior region of
the prostate, reducing the number of possible regions
to 5 or 4, respectively.3. Localize the ROS to the prostate right or left side.
4. Determine the location of the bulk of the tumor burden
to reduce the ROS to a single region.
Acoustic radiation force impulse imaging-identified
ROS that were either located either in the same region or
in the nearest-neighbor region as the histopathology PCa
lesion center were scored as successfully identifying the
histopathology lesion. ARFI ROS were also correlated
with the presence of atrophy and BPH. Atrophy and
BPH lesions were identified in all regions where present
in the histopathology slides (not just a single center
region as was done with the PCa) because these processes
can be more diffuse, and ARFI ROS were deemed coin-
cident with atrophy or BPH if the ROS intersected with
any of the regions for these benign lesion types and did
not match a PCa region in histology.
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Histopathology lesions were stratified into clinical
significance categories (Table 3) (Mazzucchelli et al.
2009). Along with lesion size, Gleason score was used
as a primary determinant of PCa clinical significance.
The Gleason grading system is based on the histologic ex-
amination of hematoxylin and eosin-stained prostatic tis-
sue sections ‘‘at relatively low magnification (310–40),
[with score determined] by the extent of glandular differ-
entiation and the pattern of growth of the tumor in the
prostatic stroma,’’ which were illustrated as nine different
patterns of growth that were striated into five different
grades (Gleason 1990). The primary pattern occupies
the greatest proportion of the tumor area, and the second-
ary pattern occupies the second-greatest proportion of the
tumor area on the slide. The grades corresponding to the
primary and secondary patterns are added together to pro-
duce an overall score that can range from 1 1 1 5 2 to
5 1 5 5 10. If only a single pattern is present, then the
associated grade is simply repeated to give the overall
score. In practice, most tumors have Gleason scores
between 31 35 6 and 51 45 9, with rare cases having
lower and higher overall scores. This grading system is
unusual in the grading of human malignancies; for most
tumors, the worst grade present in a sample determines
patient outcome. With prostatic adenocarcinoma, howev-
er, cancer-related death rates mimic the grading system,
such that a patient with a score of 3 1 4 5 7 has a better
prognosis than a patient with a score of 4 1 4 5 8, even
though tumor of grade 4 histology is present in both of
these patients (Gleason 1977; 1990; 1992).
Acoustic radiation force impulse imaging PCa
detection rates and positive predictive values (PPVs)
were calculated for all PCa lesions in this study.RESULTS
Of all clinically significant lesions, 71.4% were
detected with ARFI imaging (Fig. 4); 82.9% of these
clinically-significant lesions were in the posterior pros-
tate, and 17.1% were in the anterior prostate. ARFI imag-
ing was able to detect 79.3% of all posterior and 33.3% of
all anterior clinically significant lesions.
Among ARFI-identified ROS, 79.3%were clinically
significant PCa, with the majority having IOS scores $2Table 3. Clinical significance categories for
histopathology identified prostate cancer*
Clinically significant disease
(CSD)
Lesion volume $0.5 mL AND/
OR Gleason score .6
Clinically insignificant disease
(CINSD)
Lesion volume ,0.5 mL AND
Gleason score #6
* Lesions were also characterized by anterior or posterior location in
the prostate.
Mazzucchelli et al. 2009.(Fig. 5). Of the remaining ARFI-identified ROS, one was
atrophy and the others (IOS #2) corresponded to PCa
lesions that were not clinically significant. No ARFI
ROS were associated with BPH.
Higher-assigned ARFI imaging IOS scores for
lesions revealed higher PPVs for both CSD and CINSD
(Table 4).
In Figure 6 are two examples of PCa lesions that
were identified as highly suspicious (IOS 5 3) on ARFI
imaging and corresponded to large, clinically significant,
posterior PCa lesions, whereas in Figure 7 is an example
of a less highly suspicious lesion (IOS 5 1) that corre-
sponded to a clinically insignificant PCa lesion.
Figure 8 contains an example of an anterior, clini-
cally significant PCa lesion that was not identified as an
ROS on ARFI imaging, although in retrospect, this lesion
is clearly visible.
In Figure 9 is a small, but clinically significant PCa
lesion in the right posterior region of the prostate that was
not visible on ARFI imaging, likely because of the domi-
nant appearance of atrophy and BPH in the enlarged
central gland that compressed the peripheral zone.
Figure 10 illustrates the characteristics of the clini-
cally significant lesions that were detected and missed
in ARFI images as a function of estimated histologic
lesion volume, anterior/posterior location and Gleason
grade.Fig. 4. Pathologists localized all of the clinically significant PCa
lesions using the criteria in Table 3 on whole-mount histology
slides. ARFI imaging was able to detect 79.3% of posterior and
33.3% of anterior clinically significant lesions using the nearest-
neighbor region match. Note that the majority (82.9%) of the
clinically significant lesions were located in the posterior region.
PCa5 prostate cancer; ARFI5 acoustic radiation force impulse.
Fig. 5. Lesions on whole-mount histology were classified as
clinically significant/insignificant PCa, benign prostatic hyper-
plasia or atrophy. ROS identified in ARFI images were assigned
IOS scores (Table 3) and nearest-neighbor-matched to histology
lesions. Among the ARFI-identified lesions, 79.3% were
clinically significant, with the majority having IOS scores $2
(subhistogram). The clinically insignificant PCa lesions that
were identified overall had lower IOS scores (subhistogram),
and one ARFI ROS (IOS 5 1) corresponded to a region of
atrophy. No ARFI ROS corresponded to benign prostatic
hyperplasia, and one ARFI ROS did not correspond to any
histology-identified lesions. PCa 5 prostate cancer;
ROS 5 regions of suspicion; ARFI 5 acoustic radiation force
impulse; index of suspicion.
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Acoustic radiation force impulse images read with
the suspicion criteria outlined in Table 2 were very spe-
cific for clinically significant PCa, especially in the pos-
terior region, with 79.3% of posterior clinically
significant lesions (Fig. 4) detected. One hundred percent
of IOS 2 and 3 ARFI ROS corresponded to PCa lesions
(Table 4), and 100% of ARFI IOS 3 lesions were clini-
cally significant PCa lesions (Fig. 5, Table 4). The spec-
ificity of ARFI imaging is consistent with that of
multiparametric MRI, combining T2-weighted andTable 4. Positive predictive values and IOS scores for
CSD as well as for the presence of any cancer (CSD or
CINSD)
IOS score
Positive predictive value
CSD CSD or CINSD
3 100% 100%
2 85 % 100%
1 43 % 71%
CSD 5 clinically significant disease; CINSD 5 clinically insignifi-
cant disease; IOS 5 index of suspicion.diffusion-weighted imaging (DWI) (Gupta et al. 2013),
and greater than that of B-mode imaging alone (Eggert
et al. 2008). The high specificity of ARFI imaging could
have clinical utility in distinguishing aggressive PCa
lesions that require treatment from indolent disease that
does not need treatment and could be monitored.
Lesion size was a major determinant for visualiza-
tion in ARFI imaging. No clinically significant lesions
with histology volumes,0.4 mL (n5 5) were identified
in ARFI, all corresponding to Gleason score 7 (Fig. 10).
Small Gleason 7 lesions and larger Gleason 6 tumors
exhibit a similar likelihood of organ-confined disease,
and the presence of small Gleason 7 tumors should not
necessarily be considered an adverse finding
(Yang et al. 1999). Thus, the shortcoming of ARFI imag-
ing in identifying small tumors could be useful for
diagnostic purposes, as it may actually prevent overly
aggressive PCa treatment of small cancerous foci.
It should be noted that ARFI image lesion size does
not match the size outlined in the histology slides (Fig. 6).
The regions delineated with marker on the histology
slides correspond to cellular patterns of dysplasia that
are used to designate different Gleason grades, including
changes in nuclear morphology and other signs of cellular
atypia. These specific changes are not what we hypothe-
size generates contrast in ARFI images; instead, we
hypothesize that ARFI images have contrast related to
PCa because of increases in cellular density and intercel-
lular connectivity that change the more macrocellular
mechanical properties. We expect these changes to be
greatest at the ‘‘center’’ of evolving PCa lesions, and
therefore, we do not expect 1:1 correspondence between
the outer areas outlined in histology and the outer extents
of regions of decreased displacement in the ARFI images.
This was a motivating factor for analyzing the match of
regions where the lesions are centered, which is also the
most clinically useful feature when trying to guide a
biopsy needle to pass through the most suspicious part
of a lesion.
Six of the prostates had multifocal disease with four
or more discrete clinically significant PCa lesions; ARFI
imaging was only able to detect a PCa lesion in only one
(16.7%) of these six cases. These patients with multifocal
disease tended to have PCa lesions that were relatively
smaller in individual lesion volume (Fig. 10), which
again, is more difficult for ARFI imaging to detect.
ARFI image contrast is based on underlying differences
in tissue stiffness (Doherty et al. 2013), and poor detec-
tion of small tumors may be caused by small changes in
regional stiffness relative to large tumors.
The majority of ARFI ROS that corresponded to
clinically significant PCa lesions were large (.0.5 mL)
and had a Gleason score $7 (Fig. 10). Lesion location
was an important determinant for visualization, and
Fig. 6. Examples of ARFI imaging-identified, index of suspicion 5 3 regions of suspicion from two different study
patients (left and right columns) that corresponded to large, posterior prostate cancer index lesions (white arrows).
The ARFI images have been histogram-normalized, and the regions of suspicion were identified as large regions of
decreased displacement with contralateral contrast. BPH 5 benign prostatic hyperplasia; ARFI 5 acoustic radiation
force impulse.
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nificant PCa lesions in the anterior region, including a
large-volume (7.1 mL), Gleason 7 lesion (Figs. 8 and
10). Although retrospective review of the ARFI image
in Figure 8 may reveal regions of decreased displacement
that correspond to the lesion, the heterogeneous displace-
ment profiles in the ARFI images caused by the BPH for
this case challenged detection of this lesion, as clear uni-
lateral lesion contrast could not be established (Table 2).
Additionally, this anterior lesion existed in both the left
and right halves of the prostate, and the lack of a localized
unilateral lesion—as was the case for the lesions, forexample, in Figure 6—made it more difficult to visualize
(Fig. 8).
Overall, there were few anterior PCa lesions in
this study, but those that existed were more difficult
to visualize with ARFI imaging because of coarser
spatial sampling and reduced signal-to-noise ratio
compared with posterior PCa lesions. Some of the
challenges in imaging anterior lesions can be addressed
with a custom transducer designed specifically for
ARFI prostate imaging that could achieve better acous-
tic depth penetration and finer rotational sampling in
suspicious regions.
Fig. 7. Example of an acoustic radiation force impulse imaging-identified region of suspicion (index of suspicion 5 1)
that corresponded to a small, clinically insignificant, posterior prostate cancer lesion (white arrows). This region of sus-
picion was identified based on a small, localized region of decreased displacement. A second, smaller, clinically insig-
nificant, posterior prostate cancer lesion on the opposite side was not detected as a region of suspicion in the acoustic
radiation force impulse images.
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atrophy and BPH, to be evaluated as potential con-
founders when identifying PCa lesions. Across all
ARFI-identified ROS, only one region of atrophy was
identified as a region of low suspicion (IOS 5 1), and
one region did not correspond to any pathology (also
IOS 5 1). BPH did, however, challenge the ability to
identify peripheral PCa lesions, especially when the
BPH dominated the central gland and distorted the
normal prostate anatomy visualized in ARFI images
(Fig. 9) (Palmeri et al. 2015).
Acoustic radiation force impulse imaging is one of
several novel ultrasonic imaging modalities being
investigated to improve on the poor performance of B-
mode ultrasound imaging in delineating clinically signif-
icant PCa. A recent study byMoradi et al. (2014) using 3-
D vibro-elastography and vector machine classification
methods to identify PCa lesions based on image texture
(e.g., contrast, homogeneity, standard deviation) yielded
an area under the receiver operating characteristic curve
of 0.81 6 0.1 (Moradi et al. 2014). Shear wave elasticityimaging (SWEI) has also been studied in the prostate,
with one study achieving a positive predictive value of
69.4% using an absolute shear modulus threshold of
37 kPa (Barr et al. 2012). Compressive strain elastogra-
phy has also been used to evaluate PCa lesions, with a
quoted specificity of 83%–91% and a positive predictive
value of 69% (Cosgrove et al. 2013; Walz et al. 2011;
Zhang et al. 2011). Other non-elasticity-based ultrasound
methods using quantitative tissue characterization
schemes are also being studied in the prostate
(Braeckman et al. 2008; Feleppa et al. 2004), along
with contrast-based approaches (Ferrara et al. 2000;
Kuenen et al. 2011; Seitz et al. 2011; Wink et al. 2008).
Acoustic radiation force impulse imaging has
several advantages over the other ultrasonic imaging
modalities. Compressive strain elastography is dependent
on application of uniform compression across the entire
prostate gland, which can be challenging. This challenge
has motivated the use of strain ratios between different
regions of interest and quality maps of strain confidence
to be displayed (Cosgrove et al. 2013). ARFI imaging is
Fig. 8. Example of a prostate cancer index lesion (green and purple in histology, white arrows in images) in the anterior
stroma that was missed in ARFI imaging (no suspicious regions identified). A representative ARFI image (right) from the
midgland reveals a bright central structure corresponding to the BPH/atrophy adjacent to themidline on the patient’s right,
but the anterior stroma of the prostate could not be reliably evaluated because of stiffness heterogeneity introduced by the
BPH and atrophy. There is also shadowing and a region of decorrelation on the patient’s left resulting from a posterior
calcification in the prostate (hypo-echoic regions in the B-mode image) that can also complicate interpretation of the
ARFI image. ARFI 5 acoustic radiation force impulse; BPH 5 benign prostatic hyperplasia.
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and in fact, after achieving adequate acoustic coupling
to the rectal wall, additional compression was minimized
to avoid any elastic non-linearities in the tissue. Current
SWEI implementations use shear wave speed reconstruc-
tion kernels of finite spatial extent that can limit the
achievable spatial resolution (Rouze et al. 2012), but
ARFI image spatial resolution is higher, because it is
related to the displacement estimation kernel lengths
and beam spacing (,1 mm). Additionally, ARFI imaging
is less susceptible to the shear wave reflection artifacts
that can be present in SWE images (Deffieux et al.
2011; Rouze et al. 2012).
Acoustic radiation force impulse images in this
study were subjectively read with the target clinical
user being a urologist for real-time procedural (biopsy/
treatment) guidance. The 71.4% of clinically significant
lesions that were detected in ARFI images across all of
the prostates imaged in this study would be a great
improvement over the current TRUS imaging used during
biopsy procedures, which simply guides the completecore sampling across the entire organ during a random bi-
opsy procedure, without lesion targeting. Other imaging
technologies are being studied to guide prostate biopsies,
such as MR:ultrasound fusion, but these methods have
yielded accuracy ranging from 60% to 70% (Futterer
et al. 2015; Siddiqui 2015) and are susceptible to
modality registration errors because of prostate
deformation and varying structural contrast between
ultrasound and MR. The inherent co-registration between
ARFI and B-mode ultrasound images provides a clear
advantage over other multimodality imaging techniques.
The IOS scores (Table 2) used to quantify the ARFI
image reads could be used in more advanced machine
learning methods in combination with B-mode ultra-
sound, multiparametric MRI and other imaging and clin-
ical metrics, as has been done with vibro-elastography
(Moradi et al. 2014) and quantitative tissue-type imaging
(TTI) (Feleppa et al. 2004), but that is beyond the scope of
this work. Additionally, although the ARFI images in this
study were subjectively scored, the images could also be
more quantitatively evaluated based on the normalized
Fig. 9. Example of a small, but clinically significant prostate cancer lesion in the patient’s right posterior region of the
prostate that was missed in histogram-normalized ARFI imaging because of the dominant appearance of atrophy and BPH
in the enlarged central gland. These large BPH nodules heavily distort the typical prostate anatomy and can confound
identification of prostate cancer lesions in ARFI images. ARFI5 acoustic radiation force impulse; BPH5 benign pros-
tatic hyperplasia.
Fig. 10. Characteristics of the clinically significant lesions that ARFI imaging detected and missed as a function of
estimated histologic lesion volume and Gleason grade, shape-coded by location in the anterior (triangles) or posterior
(circles) region of the prostate. ‘‘Multifocal disease’’ is defined as a prostate having four or more cancerous foci. Note
that ARFI did not miss any of the highest Gleason grade lesions (Gleason 8 and 9), and the majority of the missed clin-
ically significant lesions had volumes,1.0 mL or were located in the anterior (triangles). The numbers on the plots asso-
ciated with some of the high-volume lesions indicate the absolute volumes of the lesions that fall off the scale of each plot.
ARFI 5 acoustic radiation force impulse.
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criteria, such as contrast and lesion heterogeneity, could
be calculated from the displacement images and input
into machine learning methods.
The ARFI imaging system implemented in this work
using a larger-aperture, side-fire linear array was signifi-
cantly improved in spatial resolution and penetration
depth compared with previous work using an end-fire
array (Zhai et al. 2012). Using the side-fire endorectal
probe, however, did require the additional overhead of
mechanical 3-D rotation and position tracking. This
research system also required separate acquisition of
high-resolution B-mode data from the ARFI imaging
data, which led to extended imaging time and introduced
the opportunity for spatial misalignment between ARFI
and B-mode imaging planes. Future ARFI imaging sys-
tems will address these challenges with more advanced
image sequencing capabilities to acquire concurrent
B-mode and ARFI imaging data, and next-generation
endorectal probes will allow for improved spatial resolu-
tion, contrast and penetration depth compared with the
ER7 B transducer used in this study.CONCLUSIONS
Acoustic radiation force impulse imaging can reli-
ably identify posterior, clinically significant PCa lesions
(79.3%). All highly suspicious (highest IOS5 3) regions
in ARFI images were clinically significant PCa lesions,
and all moderately suspicious regions (IOS 5 2 or 3)
corresponded to PCa lesions. Atrophy and BPH can
enlarge the central gland, causing peripheral zone distor-
tion, and create stiffness heterogeneity in the prostate that
confounds ARFI PCa lesion identification. In general,
ARFI imaging ROS did not coincide with benign atrophy
and BPH pathologies. This study found that ARFI imag-
ing has clinical value in identifying and differentiating
clinically significant PCa lesions in the posterior region
of the prostate, and advances in transducer technology
and modified ARFI imaging sequences should allow the
anterior region of the prostate to be more reliably interro-
gated in future studies.
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